Treating primary progressive MS - National Multiple Sclerosis Society

Skip to navigation Skip to content

Treating PPMS


Modifying the Disease Course

At the present time, there are no medications approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary-progressive MS (PPMS). Because all of the approved disease-modifying therapies work primarily by reducing inflammation in the central nervous system (CNS), they do not work as well in a disease course that is characterized by nerve degeneration rather than inflammation.

Several of the agents, including Copaxone® and an experimental drug called Rituxan, have been studied in PPMS, but unfortunately without a positive effect on progression. There are several clinical trials either recently completed or ongoing for progressive forms of MS and some are for PPMS. Read more about clinical trials in MS.

Even without an approved disease-modifying therapy, however, there is a lot that people with PPMS and their healthcare teams can do to manage the disease.


Regardless of the course of MS a person is experiencing, proactive symptom management is essential to maintaining comfort and productivity, and enhancing quality of life.


Rehabilitation specialists have an important role from the time of diagnosis helping people function optimally in spite of their MS, including enhancing mobility and promoting safety and independence.


Making Treatment & Lifestyle Decisions: Thinking About Benefits & Risks

Learn about the factors people must consider when making treatment and lifestyle decisions, including when to begin treatment, the role information overload can play in decision making, and how to weigh the benefits and risks of a treatment or lifestyle decision.

Watch now

Treatment Recommendations in Progressive MS

Amit Bar-Or, MD discusses treatment recommendations for progressive MS.

Watch now

Progressive MS

Robert Fox, MD and Amit Bar-Or, MD discuss the challenges with developing a therapy for progressive MS.

Watch now